Section Arrow
KYMR.NASDAQ
- Kymera Therapeutics
Quotes are at least 15-min delayed:2026/02/24 04:21 EST
Pre Market
Last
 --
-- (--)
Bid
35.88
Ask
111
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 88.43
+1.03 (+1.18%)
Day High 
89.49 
Prev. Close
87.4 
1-M High
89.28 
Volume 
Bid
35.88
Ask
111
Day Low
85.695 
Open
87.16 
1-M Low
67.76 
Market Cap 
6.99B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 83.06 
20-SMA 78.4 
50-SMA 78.52 
52-W High 103 
52-W Low 19.445 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.60/-3.65
Enterprise Value
7.07B
Balance Sheet
Book Value Per Share
11.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
47.07M
Operating Revenue Per Share
0.59
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABPMGC Holdings Inc.1.21-0.08-6.20%0.01PE
Pre Market 1.21 0 0.00%
LIMNLiminatus Pharma Inc0.2354+0.0064+2.79%-- 
Pre Market 0.2305 -0.0049 -2.08%
CAICaris Life Sciences Inc17.63-1.9-9.73%-- 
Pre Market 17.8 +0.17 +0.96%
RPRXRoyalty Pharma plc45.47+0.35+0.78%25.35PE
Pre Market -- -- --
MENSJyong Biotech Ltd2.73+0.72+35.82%-- 
Pre Market 2.7 -0.03 -1.10%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.